Select a Webinar

The Retina Case Forum Webinar Series 2017 is an interactive web-based virtual meeting place for healthcare practitioners to review current concepts within retina. Each live webinar allows for peer-to-peer presentation with the creation of a comprehensive differential diagnosis, the interpretation of the results of diagnostic tests, and an exploration of the potential therapeutic options by identifying the advantages and drawbacks of each approach. Pre and post testing will allow for meaningful recognition of educational goals. The discussions will be of interest to retina specialists, comprehensive ophthalmologists, residents and fellows in training, and allied health professionals.

Anti-VEGF Treatment in AMD and DME

  • Long Term AMD Treatment Strategies

    W. Lloyd Clark, MD
  • How I Incorporate Protocol T Into My Practice

    Diana V. Do, MD
  • Q & A Session

    Drs. Rishi P. Singh, W. Lloyd Clark & Diana V. Do
Launch Date

May 11, 2017

Expiration Date

May 11, 2018

Estimated Time to Complete

1 Hour

Hardware/Software Needed to Participate

High speed internet access

Target Audience

This activity is designed to meet the educational need of retina specialists, comprehensive ophthalmologists, residents and fellows in training , and allied healthcare professionals involved in the care of patients with retinal diseases.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Determine how best to treat patients with exudative AMD with anti-VEGF agents over the long term
  • Evaluate how to apply principles from clinical trials like Protocol T into clinical practice for the management of DME
Method of Participation

In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon successful completion of the post test and online evaluation/claim credit form. If you have questions about this CME activity, please contact AKH Inc. at


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

W. Lloyd Clark, MD

  • Nothing to disclose

Diana V. Do, MD

  • Consultant: Genentech, Santen, Bayer
  • Research Funding: Genentech, Regeneron, Santen

Rishi P. Singh, MD

  • Consultant: Genentech, Regeneron, Allergan
  • Contracted Research: Genentech, Regeneron, Allergan, Apellis
Planner Disclosures

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditations

  • Nothing to Disclose

MCME Global Staff and Planners

  • Nothing to Disclose

AKH Staff and Planners

  • Nothing to Disclose
Commercial Support

This activity is supported by an educational grant from: Alcon, Inc.; Bausch & Lomb; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use of Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.

Advancing Knowledge in Healthcare    mcme-logo

This activity is supported by educational grants from:

Bausch & Lomb
Regeneron Pharmaceuticals
Santen Pharmaceutical



Please answer the following pre-questions before moving on to the webinar presentation.

First Name*
Last Name*

What pharmacologic agents were eyes with diabetic macular edema randomized to in the DRCR Protocol T?


Bevacizumab and ranibizumab and laser
Aflibercept, bevacizumab, ranibizumab, and laser
Aflibercept, bevacizumab, ranibizumab, and intraocular steroid
Aflibercept, bevacizumab, and ranibizumab

All of the following are true regarding anti-VEGF dosing for exudative age-related macular degeneration EXCEPT:

Monthly dosing has demonstrated superior results in multiple clinical trials
With careful monitoring and disease-free treatment intervals, early visual acuity gains can be maintained with extended dosing frequency
Longer treatment intervals can be achieved in all patients with aggressive initial therapy
Careful monitoring of OCT at each visit is key to criteria-driven extended dosing